Scholarlink

<p>Glaucoma is a major cause of blindness. The most common type, primary open-angle glaucoma (POAG) often goes untreated due to its asymptomatic nature. Treatment aims to lower intraocular pressure (IOP), which slows POAG progression. Topical therapies, notably prostaglandin analogues (PGAs) and beta blockers are effective, but dry eyes, conjunctivitis and other issues contribute to treatment discontinuation and poor adherence. New sustained-release PGA implants may be better tolerated. Additionally, Rho kinase inhibitors are an emerging class of drugs with multiple IOP-lowering mechanisms and includes the approved therapies netarsudil (available in the USA) and ripasudil (available in Asia).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Look for glaucoma, especially in elderly, and match therapies to patients

  • 期刊论文

  • 发表日期：

    2025年2月10日

查看全文
  • Caroline Fenton,
  • Simon Fung

摘要

Glaucoma is a major cause of blindness. The most common type, primary open-angle glaucoma (POAG) often goes untreated due to its asymptomatic nature. Treatment aims to lower intraocular pressure (IOP), which slows POAG progression. Topical therapies, notably prostaglandin analogues (PGAs) and beta blockers are effective, but dry eyes, conjunctivitis and other issues contribute to treatment discontinuation and poor adherence. New sustained-release PGA implants may be better tolerated. Additionally, Rho kinase inhibitors are an emerging class of drugs with multiple IOP-lowering mechanisms and includes the approved therapies netarsudil (available in the USA) and ripasudil (available in Asia).